Mohammad Hassan Heidari
Accepted Abstracts: J Cancer Sci Ther
Introduction: PSA level in patients with prostate cancer, is usually elevated. It has been strongly recommended that PSA is used in conjunction with other tests and examinations to enhance early detection of prostate cancer but probably that isn?t enough for Stickler Specification, sHLA-G has been considered as a new tumor marker with high sensitivity for prostate cancer diagnosis comparison PSA. This study aims at evaluating the changes in levels of serum sHLA-G biomarker in patients with prostate cancer and determining the efficacy of this biomarker for diagnosis of prostate cancer. Martial and method: This descriptive-analytical study was performed on men with prostate cancer. The serum levels of sHLA-G and PSA were measured using Electrochemiluminescence (ELISA) and proteomics techniques. The data was analyzed using SPSS Ver. 11 and the level of statistical significance was considered to be p<0.05. Totally, 120 subjects participated in this study, including 40 men patients with malignant prostate tumors, 40 men patients with benign tumors and 40 healthy men. A significant increase in serum prostate and PSA levels was observed for malignant group comparing with the control group and the people with benign tumors (p<0.05). Results: The cut-off point, sensitivity and specificity of sHLA-G in diagnosis of prostate malignancies compared with prostate benign tumors and the control group were 5.6 μg/ml, 0.19 and 0.95, respectively. These levels were reported for PSA in diagnosis of prostate malignancies prostate benign tumors and the control group as 26.18, 0.75 and 0.46 U/ml respectively. Conclusion: Probably that sHLA-G serve as a good biomarker for prostate cancer diagnosis with suitable sensitivity and specificity adjacent PSA.
Cancer Science & Therapy received 3968 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 